Amgen Inc.
Profit after direct costs
Core business profitability
Bottom line profitability
Top line growth rate
Flow of revenue through cost categories to net income
| Item | Trend | 2021 | 2022 | 2023 | 2024 | 2025 | YoY Change |
|---|---|---|---|---|---|---|---|
Total Revenue | 25.98B | 26.32B | 28.19B | 33.42B | 36.74B | 9.9% | |
| Cost of Revenue | (6.45B) | (6.41B) | (8.41B) | (12.86B) | (10.73B) | -16.6% | |
Gross Profit | 19.52B | 19.92B | 19.77B | 20.57B | 26.01B | 26.5% | |
| Operating Expenses | |||||||
| Research & Development | (6.32B) | (4.43B) | (4.78B) | (5.96B) | (6.97B) | 16.9% | |
| Selling, General & Administrative | (5.37B) | (5.41B) | (6.18B) | (7.10B) | (7.05B) | -0.6% | |
| Depreciation & Amortization | (3.40B) | (3.42B) | (4.07B) | (5.59B) | (5.17B) | -7.6% | |
Operating Income (EBIT) | 7.64B | 9.57B | 7.90B | 7.26B | 10.68B | 47.1% | |
| Non-Operating Items | |||||||
| Interest Income | — | — | — | — | — | — | |
| Interest Expense | (1.20B) | (1.41B) | (2.88B) | (3.15B) | (2.75B) | -12.7% | |
| Other Income/Expenses (Net) | -938.00M | -2.22B | -42.00M | -2.65B | -1.70B | -35.8% | |
Income Before Tax | 6.70B | 7.35B | 7.86B | 4.61B | 8.98B | 94.7% | |
| Income Tax Expense | (808.00M) | (794.00M) | (1.14B) | (519.00M) | (1.26B) | 143.7% | |
Net Income | 5.89B | 6.55B | 6.72B | 4.09B | 7.71B | 88.5% | |
| Per Share Metrics | |||||||
| Earnings Per Share (Basic) | $10 | $12 | $13 | $8 | $14 | 88.1% | |
| Weighted Avg Shares Outstanding | 570.00M | 538.00M | 535.00M | 541.00M | 538.00M | -0.6% | |
| Weighted Avg Shares Outstanding (Diluted) | 573.00M | 541.00M | 538.00M | 541.00M | 542.00M | 0.2% | |
EBITDA | 11.30B | 12.17B | 14.80B | 13.36B | 16.90B | 26.5% |
Explore AMGN
AMGN in the Healthcare
Mega Cap